Latest News
All Times Eastern
- ‘It’s caused a lot of tension in our marriage’: My wife’s family comes visit, hides food and never cleans up. How do we get rid of them?
- Barron's China’s AI Clout Might Be Overstated. What to Know.
- Barron's This Company Makes Costco and Amazon’s Store Brands. Its Stock Is a Buy.
- Barron's This Carbon-Capture Stock Has Big Plans. Why It’s a Buy.
- Barron's Forget Apple and Nvidia. Why June Belongs to Small-Caps.
- Barron's Market Gains as Wall of Worry Crumbles. What Happens Next.
- Judge in FTX bankruptcy rejects media challenge, says customer names can remain secret
- Barron's Commercial Traders Are Net Long Copper. That’s a Good Sign for the Red Metal.
- Mark Zuckerberg says Meta may be ‘primary beneficiary’ of Apple Vision Pro headset
- Biogen stock rallies after full-day halt as FDA panel recommends Alzheimer’s drug for approval
to be replaced
Rogers Corp.
ROGUS
$
0.00
0.00%
After Hours
$
158.68
After Hours Volume:
703
| Close | Chg | Chg % |
|---|---|---|
| $158.68 | 1.56 | 0.99% |
Volume: 180.5K
65 Day Avg: 165.58K
155.00
Day Range
162.88
98.45
52 Week Range
271.12
Partner Center
Your Watchlists
Recently Viewed Tickers
Overview
ROG Overview
Key Data
- Open $156.90
- Day Range 155.00 - 162.88
- 52 Week Range 98.45 - 271.12
- Market Cap $2.92B
- Shares Outstanding 18.61M
- Public Float 18.32M
- Beta 1.09
- Rev. per Employee $254.41K
- P/E Ratio 31.05
- EPS $5.11
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 563.6K 05/31/23
- % of Float Shorted 3.08%
- Average Volume 165.58K
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings 2
Full Ratings
Recent News
Activist Investing Veris Residential and Rogers Stock See Action From Activist Investors
Roche gets full FDA approval for COVID-19 treatment
Roche Holding AG said late Wednesday that the Food and Drug Administration formally approved its monoclonal antibody for adults who have been hospitalized with severe COVID-19. Actemra received an emergency authorization ...
Biogen shares jump 4.7% premarket on hopes for its Alzheimer's treatment lecanemab
Biogen Inc. shares rose 4.7% in premarket trade Monday, after MorphoSys and partner Roche said a trial of a treatment for Alzheimer's disease failed to meet its main goal. German-listed shares of MorphoSys fell 30% on th...
MorphoSys shares plunge after partner Roche says Alzheimer's drug trials didn't meet goals
German-listed shares of MorphoSys lost a third of their value on Monday after its partner Roche said an Alzheimer drug trial failed. Roche slumped 4% in Zurich as the company said Phase 3 studies evaluating gantenerumab ...
Rogers stock drops sharply after DuPont walks away from purchasing the company
Rogers Corp. stock fell 42% to $96.49 in premarket trades on Wednesday after it received a termination notice from DuPont de Nemours Inc. for its $5 billion acquisition of the engineered materials company. Rogers said it...
Manufacturing DuPont Ends Rogers Acquisition. Blame China Regulators.
DuPont's $5 bln acquisition of Rogers isn't going to close on time amid regulatory talks with China
DuPont de Nemours Inc. and Rogers Corp. said their pending merger will not close as expected by the end of the third quarter of 2022 pending ongoing talks with Chinese regulators. The parties continue to hold cooperative...
Roche, Repare's licensing deal includes milestone payments worth up to $1.2 billion
Shares of Repare Therapeutics Inc. jumped 24.5% in premarket trading on Thursday, the day after the company said it signed a worldwide licensing and collaboration agreement with Roche Holding AG to develop and commercial...
Roche's lung-cancer treatment fails in a clinical trial; its stock falls 7%
Roche Holding AG said Wednesday that an experimental immunotherapy tested in combination with the cancer treatment Tecentriq failed to meet the primary co-endpoint of progression-free survival in a Phase 3 clinical trial....
Roche said experimental breast-cancer therapy didn't meet main endpoint in a Phase 2 study
Roche Holding AG said Monday that a Phase 2 clinical study evaluating giredestrant as a treatment for patients with advanced breast cancer did not meet its primary endpoint of progression-free survival. The company told i...
Preliminary U.K. research says Lilly drug can reduce the risk of death among severely ill COVID-19 patients
A new study found that baricitinib, a rheumatoid arthritis drug developed by Eli Lilly & Co. and Incyte Corp. , reduced the risk of death among patients who have been hospitalized with severe COVID-19. The new , which was...
Guggenheim downgrades Biogen to neutral from buy after U.S. proposes limiting access to Alzheimer's drug
Shares of Biogen Inc. were down 0.9% in premarket trading on Thursday after Guggenheim analysts downgraded the stock to neutral, from buy. Analysts there cite the need to wait and see how the proposing limited access to ...
Roche unit develops new testing kits to detect mutations in omicron variant
Roche and its newly acquired subsidary TIB Molbiol said Friday that they have developed three new research test kits to differentiate mutations in the omicron variant of coronavirus that causes COVID. The Swiss pharmaceut...
Rogers Corp. downgraded to neutral from buy at B. Riley
Massive Insider Trade At Rogers
on Benzinga.com
Earnings Scheduled For April 27, 2023
on Benzinga.com
Royce Investment Partners: The Value of the Long View of Small Cap
Royce Investment Partners: The Value of the Long View of Small Cap
on GuruFocus.com
Earnings Scheduled For February 28, 2023
on Benzinga.com
Looking Into Rogers's Return On Capital Employed
on Benzinga.com
Analyzing Rogers's Short Interest
on Benzinga.com
Stocks That Hit 52-Week Lows On Friday
on Benzinga.com
Why Rogers Stock Tanked Again on Thursday
on Motley Fool
Rogers Corp.
Rogers Corp. engages in the design, development, manufacture, and sale of engineered materials and components for mission critical applications. It operates through the following segments: Advanced Electronics Solutions (AES) and Elastomeric Material Solutions (EMS), and Other. The AES segment offers manufactures and sells circuit materials, ceramic substrate materials, busbars and cooling solutions for applications in electric and hybrid electric vehicles, wireless infrastructure, automotive, telematics and thermal solutions, aerospace and defense, mass transit, clean energy, connected devices and wired infrastructures. The EMS segment comprises elastomeric material solutions for critical cushioning, gasketing and sealing, impact protection, and vibration management applications. The Other segment consists elastomer components for applications in ground transportation, office equipment, consumer and other markets. The company was founded by Peter Rogers in 1832 and is headquartered in Chandler, AZ.
Competitors
| Name | Chg % | Market Cap |
|---|---|---|
| Benchmark Electronics Inc. | $879.89M | |
| Vishay Intertechnology Inc. | $3.84B | |
| Coherent Corp. | $5.44B | |
| Universal Display Corp. | $6.98B | |
| 3M Co. | $55.59B | |
| Uni-Pixel Inc. | ||
| Rubicon Technology Inc. | $2.89M |